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ABSTRACT
A simple, precise, accurate and reproducible RP-HPLC method has been developed for determination of Valsartan in Tablet 
dosage form. A Perkin Elmer HPLC series 200 with software Perkin Elmer total chrome navigator was used. The C-18 
(Kromasil, 250 × 4.6 mm) having particle size of 5µm was used. The gradient mobile phase was selected consisting of 
solution A ACN, solution B phosphate buffer of pH 3.5 added few drops of Triethylamine in of buffer solution. The run 
time of 10 min was selected. The mobile phase composition keep on varying up to the 10 min of run time. The flow rate of 
1.0 ml/min was used and Perkin Elmer series 200 UV/VIS detector wavelength was set at 250 nm. The retention time of 
Valsartan was found to be 5.19 min. The percentage recovery was found to be up to 99% to nearly 100% and percentage 
RSD was found to be less than 2.0%. Proposed method was validated for precision, accuracy, linearity range, robustness 
and ruggedness. The method was successfully applied for quantitative determination of valsartan in tablet dosage form.
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INTRODUCTION
Valsartan is chemically N-(1-Oxopentyl)-N-[[2'-(1H-tetrazol-
5-yl) [1, 1'-biphenyl]-4-yl] methyl]-L-valine.
[1-2] Valsartan is 
potent Angiotensin II receptor blocker. It is mainly used as 
anti-hypertensive drug.
[3-4] Valsartan is official in USP 1.
[5]
There  were  few  methods  reported  for  determination  of 
valsartan individually. The valine molecule of the Sertraline 
has one chiral centre. The (S) enantiomer is essentially used.
[6-7] The aim  of the present study was to develop accurate, 
precise and selective  reverse  phase HPLC assay procedure 
for  the  analysis  of  VAT  in  bulk  drug  formulation.  The 
validation of proposed method is done according to the ICH 
guideline validation was done according to ICH guidelines.
[8]
MATERIALS AND METHODS
Acetonitrile HPLC  grade,  Methanol  HPLC  grade, 
Triethylammine  HPLC  grade,  Potassium  Dihydrogen 
orthophosphate GR grade, Millipore water was used during 
the  analysis.  Chromatographic  separation  was  performed 
using  piston  pump.  Precision  loop  injector  Rheodyne  was 
used.  Perkin  Elmer  series  200  total  chrome  navigator 
software. C-18 Kromacil Kromasil column having dimension 
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of  250  × 4.6  mm  and  particle  size  of  5µm  was  used  for 
separation.
Wavelength scan
The solution of Valsartan of strength100µg/ml was prepared 
in  methanol  and  scanned  for  dictating  the  maximum 
absorbance  wavelength.  The  maximum  absorbance  of 
Valsartan was found around 250nm.
Preparation of Mobile Phase and Standard solution
Gradient condition was used for the separation. Mobile phase 
A of ACN and mobile phase B of Phosphate buffer of pH 3.5 
added with Triethylamine measuring 0.001% of Volume of 
buffer  solution.  The  mobile  Phase  B  was  filtered  through 
whatman filter paper no. 42. The stock solution of 1.0 mg/ml 
in methanol was prepared. The injection volume of 20 µl was 
kept  constant  throughout  the  analysis.  The  flow  rate  of 
1.0ml/min was selected. The total run time for 10 min was 
set and the UV detection was carried out at 250 nm. 
Preparation of sample solution 
Twenty  tablets (Valant  80,  Lupin  Pharmaceuticals  Ltd. 
Aurangabad, India) containing 80 mg of valsartan were taken 
and  average  weight  was  determined.  Weight equivalent  to 
80mg  of  Valsartan  was  taken  in  100  ml  volumetric 
volumetric flask and 50 ml of Methanol were added in that. 
The flask was sonicated for 30 min after complete sonication 
volume was made up to the mark with Methanol and shaken 
for five minutes. Dilutions were made in order to get the final 
solution of 80ppm, 100ppm and 120ppm.
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The  optimised  method  was  found  with trial  and  error  and 
steady  base  line  was  recorded.  The  standard  solution  was 
injected and chromatogram was recorded. The retention time 
of the  peak  was found to be  5.19 min. the  procedure  was 
repeated for the sample solution and peak area of standard 
and  sample  solution  were  recorded.  The  concentration  of 
drug was found out by comparing with the standard.
Table 1: Mobile Phase composition
Time (min) ACN % Buffer %
0.5 40 60
2 55 45
4 85 15
2 40 60
2 40 60
Table 2: Chromatogram of Valsartan Hydrochloride
Peak No. Name of Peak Retention Time (Min) Area µAU sec
1 Valsartan 5.19 703217.24
Table 4: Repeatability of Valsartan Hydrochloride
Conc (ppm) Area µAU sec
20 1297076.58
20 1283010.66
20 1295764.73
20 1317231.46
20 1321118.81
20 1322187.26
Average 1306064.92
R.S.D. 1.25
Table 5: Interday precision
S. 
N
o
Conc 
(ppm
)
Area 1 
µAU sec
Area 2 
µAU sec
Area 3 
µAU sec
Average 
µAU sec
% 
R.S.
D.
1. 20 1267076.
58
1283010.
66
1285764.
73
1278617.
32 0.789
2. 30 1841526.
56
1843690.
28
1852105.
27
1845774.
04 0.303
3. 40 2380476.
67
2382540.
79
2386658.
23
2383225.
23 0.132
Table 6: Intraday precision
S. 
N
o
Conc
(ppm
)
Area 1 
µAU sec
Area 2 
µAU sec
Area 3 
µAU sec
Average 
µAU sec
% 
R.S.
D.
1. 20 1317231.
46
1283010.
66
1322187.
26
1320179.1
77 0.198
2. 30 1841526.
56
1843690.
28
1843586.
87
1842891.7
93 0.033
3. 40 2380476.
67
2382540.
79
2571032.
65
2567097.8
57
0.134
3
Table 7: Recovery study
S. 
No Conc (µg/ml)
Amount 
Added 
(µg/ml)
Amount 
found 
(µg/ml)
Amount 
recovered 
(µg/ml)
% 
recovery
1. 50 40 89.34 39.34 99.27
2. 50 50 99.92 49.92 99.92
3. 50 60 109.86 59.86 99.87
RESULTS 
The method enables the quantification of the Valsartan. The 
sufficient resolution and precise quantification was obtained 
by the proposed HPLC method. The results obtained from the 
analysis were satisfactory. This method can be used for the 
routine HPLC analysis.
Method Validation
The proposed method was validated as per ICH guideline as 
follow.
Linearity
The linearity of the method was calculated by the injecting 
the  Standard  solution  of concentration  ranges  between 
10µg/ml  to  100µg/ml.  The  calibration  curve  were  plotted 
where concentration of injected solution on X- axis and area 
under  cure  the  response  factor  on  Y- axis.  The  slope  and 
intercept value for calibration curve was  y= 55373x+3204. 
The coefficient of correlation was found to be 0.996.
Repeatability
Six  injection  of  20µg/ml  were  injected  to  check  the 
repeatability response of method. The percentage R.S.D. of 
method was calculated. The R.S.D. was found to be 1.25.
Ruggedness
Interday and intraday studies were carried out to determine 
the ruggedness of the proposed method. Three replicate of 
the standard drug were injected to carry out the interday and 
intraday  study.  The  R.S.D.  and  S.D.  of  the  each  injection 
were determined. The results of the observation were found 
to be well under the limit and no marked differences were 
observed. No significant change in the chromatogram of both 
interday  and  intraday  study  proved  that  the  method  was 
rugged.
Recovery
The  accuracy  of  the  method  was  determined  by  using  the 
recovery method. The recovery method was carried out by at 
three  level  80%,  100%  and  120%  by  standard  addition 
method.  The  percentage  recovery  and  standard  deviation 
were calculated. From the analysis it was found that standard 
drug was accurate.
These studies are carried out by adding the particular amount 
of the sample solution in the stock solution. Three different 
strengths are prepared.
Robustness
Robustness of the method was determined by changing the 
flow rate of the system. The proposed flow rate of 1ml/min 
was changed to 0.8 ml/min and 1.2 ml/min. 
Table 8: Robustness study of flow rate 0.8 ml/min
Cons (ppm) Area µAU sec
50 5408454.87
50 5506228.13
50 5594254.28
Average 5502979.093
RSD 1.688945298
Table 9: Robustness study of flow rate 1.2 ml/min
Conc (ppm) Area µAU sec
50 3014713.48
50 3096293.33
50 3057557.16
Average 3056187.99
R.S.D. 1.335230548
DISCUSSION
Good  separations  of  the  chromatographic  peaks  were 
observed  and  no  interfering  peaks  were  found.  The
calibration  curve  was  linear;  the  linearity  between 
concentration  and  area  shows  its  suitability  in  in-vitro 
analysis.  The  precision  and  accuracy  of  the  method  was 
found  to  be  satisfactory.  The  recovery  study  results  were 
found satisfactory and method was robust.
Table 3: Linearity of Valsartan Hydrochloride
S. No Concentration (ppm) Area µAU sec
1. 10 589254.26
2. 20 1143180.74
3. 30 1534952.84
4. 40 2266264.24
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Fig. 1: Wavelength scan of Valsartan Hydrochloride
Fig. 2: Chromatogram of Valsartan Hydrochloride
Fig. 3: Concentration response curve of valsartan hydrochloride
The proposed HPLC method is sensitive, simple, precise and 
reproducible. It can be successfully applied for estimation of 
Valsartan  in  tablet  dosage  form  by  HPLC  method.  The 
statistical  analysis  results  that  carried  out method  are
revealing good results.
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